AEON Biopharma has submitted an Investigational New Drug (IND) application to the FDA to start a comparative pharmacodynamic study of ABP-450, a biosimilar to BOTOX. This study will use compound muscle action potential (CMAP) measurements to objectively compare neuromuscular activity between ABP-450 and BOTOX, aiming to strengthen evidence for biosimilarity. The IND submission follows a recent FDA Type 2b meeting that clarified the development pathway, emphasizing sensitive scientific assessments over traditional clinical efficacy studies. The study is expected to begin in Q1 2027, moving AEON closer to potential full-label therapeutic approval and market entry in the U.S.
AEON Biopharma's recent IND submission for a pharmacodynamic study of ABP-450 is presented here with Pluang's health sector market context. For readers following the health sector, as of Nov 09, 2026 18:41 WIB, 108 of 150 priced US health stocks on Pluang rose while 26 fell. Notable movers include FLNA at USD 0.48 (+6.01%), LFST at USD 12.99 (-5.66%), and IONS at USD 37.25 (-5.50%).
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
Credit Agricole Toulouse 31 disclosed its weekly transactions involving the buyback of its cooperative investment certificates (CCI) from November 2 to November 6, 2026. The bank repurchased varying volumes daily, with prices ranging around 98.82 to ...
